Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2

Swart, Maarten; Lubbe, Joan van der; Huizen, Ella van; Verspuij, Johan; Gil, Ana Izquierdo; Choi, Ying; Daal, Chenandly; Perkasa, Aditya; Wilde, Adriaan de; Claassen, E.; Jong, Rineke de; Wiese, Katrin E.; Cornelissen, Lisette A. H. M.; Es, M. van; Heerden, Marjolein van; Kourkouta, Eleni; Tahiri, Issam; Mulders, Michel; Vreugdenhil, Jessica; Boer, Karin Feddes-de; Muchene, Leacky; Tolboom, Jeroen; Dekking, Liesbeth; Juraszek, Jarek; Vellinga, Jort; Custers, Jerome; Bos, Rinke; Schuitemaker, Hanneke; Wegmann, Frank; Roozendaal, Ramon; Kuipers, Harmjan; Zahn, Roland

doi:10.1038/s41541-023-00633-x

Cited by 2 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, with the currently updated (bivalent) mRNA vaccines, which in our study showed a better performance to protect against Omicron subvariants when compared with the original versions, an updated version of Ad26.COV2.S should be considered and evaluated. Other studies in NHP 24 and mice 25 showed that a booster with an Omicron BA.1-spike Ad26.COV2.S-based vaccine (Ad26.COV2.S.529) improved the immune responses and showed a marked reduction in lung viral loads and pathology compared with the original vaccine (Ad26.COV2.S). Previous studies using hamsters immunized with Ad26.COV2.S- and BNT162b2 also showed high titers of binding and neutralizing antibodies against the ancestral (USA-WA1/2020) and VOCs (Alpha, Beta and Gamma) at 4 weeks post- vaccination 24 – 26 .…”

Section: Discussionmentioning

confidence: 97%

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

et al. 2023

View full text Add to dashboard Cite

The SARS-CoV-2 Omicron subvariant BA.5 rapidly spread worldwide and replaced BA.1/BA.2 in many countries, becoming globally dominant. BA.5 has unique amino acid substitutions in the spike protein that both mediate immune escape from neutralizing antibodies produced by immunizations and increase ACE2 receptor binding affinity. In a comprehensive, long-term (up to 9 months post primary vaccination), experimental vaccination study using male Syrian hamsters, we evaluate neutralizing antibody responses and efficacy against BA.5 challenge after primary vaccination with Ad26.COV2.S (Janssen) or BNT162b2 (Pfizer/BioNTech) followed by a homologous or heterologous booster with mRNA-1273 (Moderna) or NVX-CoV2373 (Novavax). Notably, one high or low dose of Ad26.COV2.S provides more durable immunity than two primary doses of BNT162b2, and the NVX-CoV2373 booster provides the strongest augmentation of immunity, reduction in BA.5 viral replication, and disease. Our data demonstrate the immunogenicity and efficacy of different prime/boost vaccine regimens against BA.5 infection in an immune-competent model and provide new insights regarding COVID-19 vaccine strategies.

show abstract

Section: Discussionmentioning

confidence: 97%

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

et al. 2023

View full text Add to dashboard Cite

show abstract

“…For the studies in which spike antigen was used, a peptide pool composed of 156 15-mers peptides overlapping by 11 amino acids of the SARS-CoV-2 Wuhan-Hu-1 (B) spike protein [ 77 ] was used in the IFN-γ ELISpot.…”

Section: Methodsmentioning

confidence: 99%

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses

Marquez-Martinez,

Salisch,

Serroyen

et al. 2024

PLoS ONE

Self Cite

View full text Add to dashboard Cite

Non-replicating adenovirus-based vectors have been broadly used for the development of prophylactic vaccines in humans and are licensed for COVID-19 and Ebola virus disease prevention. Adenovirus-based vectored vaccines encode for one or more disease specific transgenes with the aim to induce protective immunity against the target disease. The magnitude and duration of transgene expression of adenovirus 5- based vectors (human type C) in the host are key factors influencing antigen presentation and adaptive immune responses. Here we characterize the magnitude, duration, and organ biodistribution of transgene expression after single intramuscular administration of adenovirus 26-based vector vaccines in mice and evaluate the differences with adenovirus 5-based vector vaccine to understand if this is universally applicable across serotypes. We demonstrate a correlation between peak transgene expression early after adenovirus 26-based vaccination and transgene-specific cellular and humoral immune responses for a model antigen and SARS-CoV-2 spike protein, independent of innate immune activation. Notably, the memory immune response was similar in mice immunized with adenovirus 26-based vaccine and adenovirus 5-based vaccine, despite the latter inducing a higher peak of transgene expression early after immunization and a longer duration of transgene expression. Together these results provide further insights into the mode of action of adenovirus 26-based vector vaccines.

show abstract

Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2

Cited by 2 publications

References 60 publications

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters

Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses

Contact Info

Product

Resources

About